Meditech Research Limited

Phase IIb trial of HyCAMP to be initiated

Published in Cancer Law Weekly, September 18th, 2004

Meditech Research Limited (MTR) announced its decision to proceed with the second stage of its phase II clinical trial of HyCAMP in colorectal cancer patients, having successfully achieved its objectives of reducing treatment toxicity while maintaining tumor response.

A major problem with a widely used treatment, irinotecan (Camptosar) has been the high incidence of gastrointestinal toxicity resulting in reported withdrawals from treatment of approximately 30% of patients.

After reviewing results of patients enrolled in the pharmacokinetic stage of Meditech's HyCAMP trial, the clinical trial investigators have reported no withdrawals from the trial...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2004-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry